Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and ameliorates acute murine colitis

International Immunopharmacology

Volumn 7, Issue 2, 2007, Pages 241-248

  Lee, Jong Yeul ^a   Kim, Joo Sung ^a   Kim, Jung Mogg ^b   Kim, Nayoung ^a   Jung, Hyun Chae ^a   Song, In Sung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

Author keywords

Inflammatory bowel disease; Intestinal epithelial cells; Murine colitis; NF B; Simvastatin; Statin

Indexed keywords

DEXTRAN SULFATE; DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; BODY WEIGHT; CELL LINE; COLITIS; DISEASE SEVERITY; DNA BINDING; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; COLITIS; EPITHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; I-KAPPA B PROTEINS; INTERLEUKIN-8; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845943499     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.10.013     Document Type: Article

References (50)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
2. Targan S.R., and Murphy L.K. Clarifying the causes of Crohn's. Nat Med 1 (1995) 1241-1243
3. Isaacs K.L., Lewis J.D., Sandborn W.J., Sands B.E., and Targan S.R. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 11 Suppl 1 (2005) S3-S12
4. Nikolaus S., Bauditz J., Gionchetti P., Witt C., Lochs H., and Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42 (1998) 470-476
5. Pallone F., and Monteleone G. Regulatory cytokines in inflammatory bowel disease. Aliment Pharmacol Ther 10 Suppl 2 (1996) 75-79
6. Plevy S.E., Landers C.J., Prehn J., Carramanzana N.M., Deem R.L., Shealy D., et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159 (1997) 6276-6282
7. Jobin C., and Sartor R.B. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol 278 (2000) C451-C462
8. Neurath M.F., Becker C., and Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 43 (1998) 856-860
9. Schottelius A.J., and Baldwin Jr. A.S. A role for transcription factor NF-κB in intestinal inflammation. Int J Colorectal Dis 14 (1999) 18-28
10. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115 (1998) 357-369
11. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42 (1998) 477-484
12. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., and Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2 (1996) 998-1004
13. Jobin C., and Sartor R.B. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 6 (2000) 206-213
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
15. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
16. Fenton II J.W., Shen G.X., Minnear F.L., Brezniak D.V., Jeske W.P., Walenga J.M., et al. Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol Oncol Clin North Am 14 (2000) 483-490
17. Davignon J., and Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol (Paris) 62 (2001) 101-112
18. Amin-Hanjani S., Stagliano N.E., Yamada M., Huang P.L., Liao J.K., and Moskowitz M.A. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 (2001) 980-986
19. Puddu P., Puddu G.M., and Muscari A. HMG-CoA reductase inhibitors: is the endothelium the main target?. Cardiology 95 (2001) 9-13
20. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
21. Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H., et al. Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther 41 (2003) 397-401
22. Hernandez-Presa M.A., Ortego M., Tunon J., Martin-Ventura J.L., Mas S., Blanco-Colio L.M., et al. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57 (2003) 168-177
23. Viedt C., Shen W., Fei J., Kamimura M., Hansch G.M., Katus H.A., et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol 98 (2003) 353-361
24. Okamoto T., Yamagishi S., Inagaki Y., Amano S., Koga K., Abe R., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16 (2002) 1928-1930
25. Lin R., Liu J., Peng N., Yang G., Gan W., and Wang W. Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 28 (2005) 1630-1634
26. Dechend R., Fiebler A., Lindschau C., Bischoff H., Muller D., Park J.K., et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 14 (2001) 55S-61S
27. Sasaki M., Bharwani S., Jordan P., Joh T., Manas K., Warren A., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 305 (2003) 78-85
28. Naito Y., Katada K., Takagi T., Tsuboi H., Isozaki Y., Handa O., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 17 (2006) 997-1004
29. Jobin C., Haskill S., Mayer L., Panja A., and Sartor R.B. Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J Immunol 158 (1997) 226-234
30. Kim J.S., and Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signaling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology 115 (2005) 375-387
31. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163 (1999) 3474-3483
32. Haller D., Russo M.P., Sartor R.B., and Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 277 (2002) 38168-38178
33. Cooper H.S., Murthy S.N., Shah R.S., and Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69 (1993) 238-249
34. Dieleman L.A., Palmen M.J., Akol H., Bloemena E., Pena A.S., Meuwissen S.G., et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114 (1998) 385-391
35. Jobin C., Hellerbrand C., Licato L.L., Brenner D.A., and Sartor R.B. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 42 (1998) 779-787
36. Pruefer D., Scalia R., and Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 19 (1999) 2894-2900
37. Fischetti F., Carretta R., Borotto G., Durigutto P., Bulla R., Meroni P.L., et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 135 (2004) 186-193
38. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
39. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22 (2002) 1194-1199
40. Morikawa S., Takabe W., Mataki C., Kanke T., Itoh T., Wada Y., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9 (2002) 178-183
41. Dichtl W., Dulak J., Frick M., Alber H.F., Schwarzacher S.P., Ares M.P., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23 (2003) 58-63
42. Wei C.Y., Huang K.C., Chou Y.H., Hsieh P.F., Lin K.H., and Lin W.W. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol 69 (2006) 960-967
43. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
44. Reddy B.S., Wang C.X., Kong A.N., Khor T.O., Zheng X., Steele V.E., et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66 (2006) 4542-4546
45. Kucharczak J., Simmons M.J., Fan Y., and Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22 (2003) 8961-8982
46. Riedl S.J., and Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5 (2004) 897-907
47. Sasazuki T., Okazaki T., Tada K., Sakon-Komazawa S., Katano M., Tanaka M., et al. Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol Immunol 41 (2004) 547-551
48. Luo J.L., Maeda S., Hsu L.C., Yagita H., and Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297-305
49. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
50. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115 (2005) 2625-2632